Most material SEC filings — August 24, 2026

BioXcel Therapeutics amended its April 2022 Credit Agreement with Oaktree Fund Administration (administrative agent) and lenders. The amendment requires the company to enter definitive agreements for either: (A) full cash repayment of all loan obligations by August 28, 2026, or (B) an alternative capital solutions transaction acceptable to Majority Lenders. The company must also cooperate in good faith with lenders regarding regulatory processes affecting material assets through that same date.

Comstock closed the sale of 100% of its mining subsidiaries (Comstock Mining LLC, Processing LLC, Exploration LLC, Real Estate Inc.) and all related assets to Mackay Precious Metals Inc. (subsidiary of Mackay Gold Silver Corp.) for aggregate consideration valued at >$45M: $20M cash received plus 2M Mackay shares (~$4.5M), with $7M due in 18 months. Comstock expects to record a $10M–$12M non-taxable gain, retains 1.5% NSR royalty on precious metals/minerals, has contingent $10M payment if Mackay constructs mine or achieves $500M+ sale within 7 years, and projects $1.5M annual operating cost savings.

On August 19, 2026, U.S. District Judge Stephen V. Wilson modified a 2020 consent decree governing the CA-324 and CA-325 onshore pipelines (acquired by Sable in February 2024). The court relieved original defendant Plains All American Pipeline of ongoing obligations, transferred regulatory authority from California's OSFM to federal PHMSA, and incorporated California state pipeline safety standards into the decree itself. Sable restarted the pipelines on March 14, 2026 (after a DPA order from Energy Secretary Chris Wright on March 13, 2026) without required state approval, violating the consent decree. The court imposed $1.449 million in stipulated penalties ($2,000–$5,500/day for 159 days across two pipelines) but denied an injunction since PHMSA now has authority. The court upheld the DPA order's preemption of California state law and trespass claims, and remanded a state-court preliminary injunction case back to state court on timeliness grounds.

KLX Energy Services Holdings, Inc. registered a transferable rights offering on August 24, 2026, under Form S-3. Eligible holders (common shareholders and warrant holders as of August 21, 2026 record date) receive 1 subscription right per share/warrant. Each right purchases 3.885 common shares at $1.49/share, totaling up to 83,876,809 shares issuable. Rights trade on Nasdaq under symbol KLXER through September 23, 2026 expiration. Over-subscription privilege available; 9.995% ownership cap enforced. Computershare serves as subscription agent.

Precision BioSciences announced first patient dosing in August 2026 in the Phase 1/2 FUNCTION-DMD clinical trial of PBGENE-DMD, an in vivo gene-editing therapy for Duchenne muscular dystrophy. The trial targets ambulatory DMD patients aged 2–7 with exons 45–55 mutations (affecting ~60% of DMD patients); first site was Arkansas Children's Hospital. Initial safety data expected by year-end 2026. No financial figures, partnership amounts, or share issuances disclosed in this filing.

Soluna completed acquisition of 397 acres in Briscoe County, Texas (exceeding the originally planned 300 acres) for Project Dorothy 3, a planned 300 MW renewable-first AI computing campus. The land sits adjacent to Soluna's existing Projects Dorothy 1 and 2 and the 150 MW Briscoe Wind Farm acquired in April 2026, enabling direct behind-the-meter access to owned generation. The purchase price was not disclosed in the filing.

Callan JMB Inc. (via subsidiary Callan Power LLC) agreed to acquire Reger Oil's Williston Basin oil and gas portfolio (26 Montana leases, ~8,000 acres) for $10M in Series A Perpetual Convertible Preferred Stock (1,000 shares at $10,000 stated value each) plus $2M cash (due by Dec 31, 2026). Michael Reger becomes President of Buyer and joins Callan's board. Closing scheduled for Sept 22, 2026. Reger retains certain liabilities; Buyer assumes production obligations under existing Chandler Energy development agreement.

In a patent infringement lawsuit brought by Beckman Coulter, Inc. in U.S. District Court for Delaware, a jury found in Cytek's favor on three of four asserted claims (noninfringement and invalidity). However, the jury found infringement under the doctrine of equivalents on one claim and awarded damages of $20 million in lost profits plus $36 million in royalties (total $56 million). Cytek states it will challenge the single adverse finding and damages award via post-verdict motions and potentially appeal to the Federal Circuit.